Collagen fiber orientation as quantified by small angle light scattering in wounds treated with transforming growth factor-beta2 and its neutalizing antibody.
The purpose of this study was determine quantitative differences in collagen fiber orientation in a wound healing model in the presence of transforming growth factor-beta2 and anti-transforming growth factor-beta2,3 antibody. Full-thickness wounds were made in the paravertebral area of two young pigs. Wounds were treated once, topically, with either transforming growth factor-beta2 or anti-transforming growth factor-beta2 antibody, or with methylcellulose gel. Control wounds were left untreated. Tissue biopsies were obtained from each wound on days 7, 14 and 46 post wounding. Tissue sections were stained with hematoxylin and eosin, and collagen fiber preferred orientation was quantified using small angle light scattering. Our results indicated that wounds treated with transforming growth factor-beta2 and anti-transforming growth factor-beta2,3 antibody had a significantly higher degree of orientation of collagen fibers than normal unwounded skin on days 7, 14 and 46 (p < 0.001). Transforming growth factor-beta2- treated wounds had a higher degree of orientation of collagen fibers than control wounds on days 7 and 14 (p < 0.001), and control wounds displayed a higher degree of orientation than wounds treated with anti-transforming growth factor-beta2,3 and normal unwounded skin at all time points (p < 0.001). These results suggest that differences in the dermal collagen degree of orientation correlate with scarring, and show that small angle light scattering can be used quantitatively to assess differences in the collagen fiber architecture of dermal wounds.
Department of Dermatology and Cutaneous Surgery, School of Medicine, University of Miami, Florida, USA.
L E
LE
Bowes
M C
MC
Jimenez
E D
ED
Hiester
M S
MS
Sacks
J
J
Brahmatewari
P
P
Mertz
W H
WH
Eaglstein
D000287:Administration, Topical; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D002921:Cicatrix / Q000473:pathology; D003094:Collagen / Q000187:drug effects* / Q000648:ultrastructure; D004396:Coloring Agents; D004195:Disease Models, Animal; D004801:Eosine Yellowish-(YS); D005456:Fluorescent Dyes; D005500:Follow-Up Studies; D006416:Hematoxylin; D008027:Light; D008747:Methylcellulose; D010592:Pharmaceutic Aids; D012542:Scattering, Radiation; D012867:Skin / Q000187:drug effects / Q000293:injuries* / Q000473:pathology; D013552:Swine; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D014945:Wound Healing
D000906:Antibodies; D004396:Coloring Agents; D005456:Fluorescent Dyes; D010592:Pharmaceutic Aids; D016212:Transforming Growth Factor beta; D008747:Methylcellulose; D003094:Collagen; D004801:Eosine Yellowish-(YS); D006416:Hematoxylin